Skip to main content
SpringerLink
Log in

Therapeutic Advances in Small Cell Lung Cancer Management

  • Chapter
  • First Online:
Lung Cancer

Part of the book series: Current Cancer Research ((CUCR))

  • 785 Accesses

Abstract

Small cell lung cancer is a recalcitrant malignancy that poses significant management challenges for the treating physician. Recent developments in our understanding of the biology of this disease have created opportunities to advance the field of small cell lung cancer treatment. Some of the most notable recent breakthroughs include immunotherapy, and novel approaches are being developed to leverage new targets for therapeutic intervention. Promising work is being done in many domains, including DNA repair, cell cycle regulation and epigenetics. With all of these discoveries, there is reason to be hopeful for further progress in the years ahead.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic and end results database. J Clin Oncol 24(28):4349–4544

    Article  Google Scholar 

  2. Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP (2019) Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer 19(5):289–297

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gay CM, Stewart CA, Park EM et al (2021) Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39(3): 346–360

    Google Scholar 

  4. Tian Y, Zhai X, Han A, Zhu H, Yu J (2019) Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. J Hematol Oncol 12(67):1–12

    Google Scholar 

  5. Murray N, Coy P, Pater JL (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11(2):336–344

    Article  CAS  PubMed  Google Scholar 

  6. Vallieres E, Shepherd FA, Crowley J et al (2009) The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming(seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 4(9):1049–1059

    Article  PubMed  Google Scholar 

  7. Fox W, Miller AB, Tall R (1966) Comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat celled carcinoma of the bronchus. First report to the Medical Research Council by the working-party on the evaluation of different methods of therapy in carcinoma of the bronchus. Lancet 2(7471):979–986

    Google Scholar 

  8. Fox W, Scadding JG (1973) Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. Ten-year follow-up. Lancet 2(7820):63–65

    Article  CAS  PubMed  Google Scholar 

  9. Martini N, Wittes RE, Hilaris BS et al (1975) Oat cell carcinoma of the lung. Clin Bull 5(4):144–148

    CAS  PubMed  Google Scholar 

  10. Yu JB, Decker RH, Detterbeck FC, Wilson LD (2010) Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 5(2):215–219

    Article  PubMed  Google Scholar 

  11. Wong AT, Rineer J, Schwartz D, Schreiber D (2016) Assessing the impact of postoperative radiation therapy for completely resected limited-stage small cell lung cancer using database. J Clin Oncol 11(2):242–248

    Google Scholar 

  12. Yang CF, Chan DY, Speicher PJ, Gulack BC, Wang X, Hartwig MG, Onatis MW, Tong BC, D’Amico TA, Berry MF, Marpole DH (2016) Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer. J Clin Oncol 34(10):1057

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gaspar LE, Gay GE, Crawford J et al (2005) Limited -stage small cell lung cancer (stages I-III): observations from the National Cancer Database. Clin Lung Cancer 6:355–360

    Article  PubMed  Google Scholar 

  14. Janne PA, Freidlin B, Saxman S et al (2002) Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 95(7):1528–1538

    Article  PubMed  Google Scholar 

  15. Evans WK, Shepherd FA, Feld R et al (1985) VP-16 and cisplatin as first line therapy for small-cell lung cancer. J Clin Oncol 3(11):1471–1477

    Article  CAS  PubMed  Google Scholar 

  16. Sundstrum S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 year’s follow up. J Clin Oncol 20(24):4665–4672

    Article  Google Scholar 

  17. Pujol JL, Carestia L, Daures JP (2000) Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trial of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83(1):8–15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, Meert AP, Vermylen P, Sculier JP, European Lung Cancer Working Party (ELCWP) (2000) A systemic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30(1):23–36

    Article  CAS  PubMed  Google Scholar 

  19. Rossi A, Di Maio M, Chiodini P et al (2012) Carboplatin- or cisplatin-based chemotherapy in the first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 30(14):1692–1698

    Article  CAS  PubMed  Google Scholar 

  20. Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10(6):890–895

    Article  CAS  PubMed  Google Scholar 

  21. Pignon JP, Arriagada R, Ihde DC et al (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327(23):1618–1624

    Article  CAS  PubMed  Google Scholar 

  22. Takada M, Fukuoka M, Kawahara M et al (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cosplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20(14):3054–3060

    Article  CAS  PubMed  Google Scholar 

  23. Fried DB, Morris DE, Poole C et al (2004) Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22(23):4837–4845

    Article  PubMed  Google Scholar 

  24. De Ruysscher D, Pijls-Johannesma M, Bentzen SM et al (2006) Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24(7):1057–1063

    Article  PubMed  Google Scholar 

  25. NCCN guidelines, version 1.2019, 10/10/18. 12/29/18

    Google Scholar 

  26. Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O’Brien M, Pantrotto J, Surmonth V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F, CONVERT Study Team (2017) Concurrent once-daily versus twice daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomized, superiority trial. Lancet Oncol 18(8):1116–1125

    Article  PubMed  PubMed Central  Google Scholar 

  27. Gregory MM, Belderbos JS, Kepka L, Martel MK, Jeremic B (2008) Report from the International Atomic Energy Agency (IAEA) consultant,s meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). Int J Radiat Oncol Biol Phys 72(2):327–334

    Article  Google Scholar 

  28. Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livinsgston R, Weiss GR, Hicks WJ, Gandara DR et al (1995) Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13(7):1632–1641

    Article  PubMed  Google Scholar 

  29. Videtic GM, Stitt LW, Dar AR et al (2003) Continued cigarette smoking by patient receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 21(8):1544–1549

    Article  PubMed  Google Scholar 

  30. clinicaltrials.gov. 2019 [cited 2019 January 13, 2019]; a phase III, randomized, double-blind, placeo-controlled, multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as consolidation treatment for patients with Stage I-III Limited Disease small-cell lung cancer who have not progressed following concurrent chemoradiation therapy (ADRIATIC) clinicaltrials.gov for STIMULI (NCT02046733), NRG-LU005 (NCT03811002), KEYLYNK-013 (NCT04624204)

  31. Auperin A, Arriagada R, Pignon JP et al (1999) Prophylactic cranial irradiation for patient with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341(7):476–484

    Article  CAS  PubMed  Google Scholar 

  32. Sagman U, Lishner M, Maki E, Sheperd FA, Haddad R, Evans WK (1992) Secondary malignancies following diagnosis of small-cell lung cancer. J Clin Oncol 10:1525–1533

    Article  CAS  PubMed  Google Scholar 

  33. Tucker MA, Murray N, Shaw EG, Ettinger DS, Mabry M, Hubber MH (1997) Second primary cancer related to smoking and treatment of small-cell lung cancer. J Natl Cancer Inst 279(10):726G

    Google Scholar 

  34. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO (1992) Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposde and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10(2):282–291

    Article  CAS  PubMed  Google Scholar 

  35. Fukuoka M, Furuse K, Saijo N et al (1991) Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternations of these regimens in small-cell lung cancer. J Natl Cancer Inst 83(12):855–861

    Article  CAS  PubMed  Google Scholar 

  36. Horn L, Mansfield AS, Szczesna A et al (2018) First-line atezolizumab plus chemotherapy in extensive- stage small-cell lung cancer. N Engl J Med 379(23):2220–2229

    Article  CAS  PubMed  Google Scholar 

  37. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair M, Ozguroglu M, Ji J, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev N, Armostrong J, Byrne N, Shire N, Jiang H, Goldman J (2019) Durvalumab plus platinum-etoposide versus platinum etoposide in first-line treatment of extensive-stage small cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase 3 trial. Lancet 394(10212):1929–1939

    Article  CAS  PubMed  Google Scholar 

  38. Rudin CM, Awad MM, Navarro A et al (2020) KEYNOTE-604: pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage small-cell lung cancer (SCLC). J Clin Oncol 38(suppl):abstr 9001

    Article  Google Scholar 

  39. Bristol-Myers Squibb Announces CheckMate −451 Study did not meet primary endpoint of overall survival with opdivo plus yervoy vs. placebo as a maintenance therapy in patients with extensive-stage small cell lung cancer after completion of first-line... (2018) https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-checkmate-451-study-did-not-meet

  40. Slotman BJ, van Tinteren H, Praag JO et al (2015) Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 385(9962):36–42

    Article  PubMed  Google Scholar 

  41. Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, Keijser A, Faivre-Finn C, Senan S (2015) Radiotherapy for extensive stage small-cell lung cancer – Author’s reply. Lancet 385(9975):1292–1293

    Article  PubMed  Google Scholar 

  42. Slotman B, Faivre-Finn C, Kramer G et al (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer, prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357(7):664–672

    Article  CAS  PubMed  Google Scholar 

  43. Takahashi T, Yamanaka T, Seto T et al (2017) Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-Label, phase 3 trial. Lancet 18(5):663–671

    Article  Google Scholar 

  44. Son CH, Jimenez R, Niemierko A, Loeffler JS, Oh KS, Shih HA (2012) Outcomes after whole brain reirradiation in patients with brain metastases. Int J Radiat Oncol Biol Phys 82(2):e167–e172

    Article  PubMed  Google Scholar 

  45. Sadikov E, Bezjak A, Yi QL, Wells W, Dawson L, Millar BA, Laperriere N (2007) Value of whole brain re-irradiation for brain metastases- single centre experience. Clin Oncol (R Coll Radiol) 19(7):532–538

    Article  CAS  Google Scholar 

  46. Harris S, Chan MD, Lovato JF, Ellis TL, Tatter SB, Bourland JD, Munley M, deGuzman AF, Shaw EG, Urbanic JJ, McMullen KP (2012) Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer. Int J Radiat Oncol Biol Phys 82(1):e53–e59

    Article  Google Scholar 

  47. Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, Werner-Wasik M, Videtic GM, Garces YI, Choy H (2011) Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited disease small cell lung cancer. Int J Radiat Oncol Biol Phys 81(1):77–84

    Article  PubMed  Google Scholar 

  48. Brown PD, Pugh S, Laack NN et al (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 10(15):1429–1437

    Article  CAS  Google Scholar 

  49. Gondi V, Deshmukh S, Brown PD et al (2018) Preservation of neurocognitive finction with conformal avoidance of the hippocampus during whole-brain radiotherapy for brain metastases: Preliminary result of phsae III trial NRG Oncology CC001. 2018 annual meeting of ASTRO. Abstract LBA9

    Google Scholar 

  50. Owonikoko TK, Behera M, Chen Z et al (2012) A systematic analysis of efficacy of second line chemotherapy in sensitive and refractory small cell lung cancer. J Thorac Oncol 7(5):866–872

    Article  PubMed  PubMed Central  Google Scholar 

  51. Postmus PE, Berendsen HH, van Zandwijk N, Splinter TA, Burghouts JT, Bakker W (1987) Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 23(9):1409–1411

    Article  CAS  PubMed  Google Scholar 

  52. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jager D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharms P, Harbison CT, Lin CS, Christensen O, Calvo E (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17(7):883–895

    Article  CAS  PubMed  Google Scholar 

  53. Hellman MD, Ott PA, Zugazagoitia J et al (2018) Nivolumab (nivo) +/− ipilulumab (ipi) in advanced small-cell lung cancer (SCLC): first report of a randomized expansion cohort from CheckMate 032. J Clin Oncol 35(suppl):abstr 8503

    Google Scholar 

  54. Bristol-myers squibb announces phase 3 CheckMate-331 study does not meet primary endpoint of overall survival with opdivo versus chemotherapy in patients with previously treated relapsed small cell lung cancer (2018) https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-phase-3-checkmate-331-study-doe

  55. Hellman MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atamca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Chang H, Geese WJ, Antonia SJ (2018) Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 33(5):853–861

    Google Scholar 

  56. Cheol Chung H, Lopez-Martin JA, Kao SC, Miller WH, Ros W, Gao B, Marabelle A, Gottfried M, Zer A, Delord JP, Penel N (2018) Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. J Clin Oncol 36(15_suppl):8506

    Article  Google Scholar 

  57. Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, Piperdi B, Mehnert JM (2017) Pembrolizumab in patients with extensive stage small cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol 35(34):3823–3829

    Article  CAS  PubMed  Google Scholar 

  58. Cavallo J (2019) AACR 2019: data analysis shows activity of pembrolizumab in pretreated patients with advanced small cell lung cancer. Available from: http://www.ascopost.com

  59. Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J (2020) Lurbinectidin as second-line threatment for patient with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 21(5):645–654

    Article  CAS  PubMed  Google Scholar 

  60. O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24(34):5441–5447

    Article  PubMed  CAS  Google Scholar 

  61. von Pawel J, Schiller JH, Shepherd FA et al (1999) Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17(2):658

    Article  Google Scholar 

  62. Pietanza MC, Kadota K, Huberman K et al (2012) Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 18(4):1138–1145

    Article  CAS  PubMed  Google Scholar 

  63. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J et al (2012) Proetomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2:798–811

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Owonikoko T, Dahlberg S, Sica G et al (2017) Randomized trial of cisplatin and etoposide in combination with velaparib or placebo for extensive stage small cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol 35(15_suppl):8505

    Article  Google Scholar 

  65. Pietanza CM, Waqar S, Krug LM et al (2018) Randomized, double blind, phase II study of temozolomide in combination with either velaparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol 36(23):2386–2394

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Lok BH, Gardner E, Scheenberger VE et al (2017) PARP inhibitor activity correlates with SLFN-11 expression and demonstrates synergy with temozolomide in small-cell lung cancer. Clin Cancer Res 23:523–525

    Article  CAS  PubMed  Google Scholar 

  67. Syljuasen RG, Hasvold G, Hauge S et al (2015) Targeting lung cancer through inhibition of checkpoint kinases. Front Genet 6:70

    PubMed  PubMed Central  Google Scholar 

  68. Hwang DH, Sun H, Rodig SJ et al (2015) Myc protein expression correlates with MYC amplification in small-cell lung carcinoma. Histopathology 67:81–89

    Article  PubMed  Google Scholar 

  69. Sos ML, Dietlein F, Peifer M et al (2012) A framework for the identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci USA 109:17034–17039

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Melichar B, Adenis A, Lockhart AC et al (2015) Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, and gastro-oesophageal adenocarcinoma, a five arm phase 2 study. Lancet Oncol 16:395–405

    Article  CAS  PubMed  Google Scholar 

  71. Owonikoko T, Nackaerts K, Csozi T, Ostoros G, Baik C, Ullmann CD, Zagadailov E, Sheldon-Waniga E, Huebner D, Leonard EJ, Spigel D (2017) OA05.05 randomized phase 32 study: alisertib (MLN8237) of placebo + paclitaxel as second-line therapy for small-cell lung cancer (SCLC). J Thorac Oncol 12(1 supplement):S261–S262

    Article  Google Scholar 

  72. Luchenko VL, Salcido CD, Zhang Y et al (2011) Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small-cell lung cancer. Cell Cycle 10:3119–3128

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD (2018) Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anti-Cancer Drugs 29(5):457–465

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Kunnimalayaan M, Chen H (2007) Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist 12(5):535–542

    Article  CAS  Google Scholar 

  75. Saunders LR, Bankovich AJ, Anderson WC et al (2015) A DLL3-targeted antibody-drug conjugate eradicates high grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 7:302ra136

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Carbone DP, Morgensztern D, Moulec SL et al (2018) Efficacy and safety of rovalpituzumab teserine in patients with DLL3-expressing, >3rd line small cell lung cancer: results from the phase 2 TRINITY trial. J Clin Oncol 36:abstract 8507

    Article  Google Scholar 

  77. Study evaluating safety, tolerability and PK of AMG757 in adults with small cell lung cancer (2019). Available from: www.cancer.gov

Download references

Author information

Authors and Affiliations

  1. Department of Medicine (Medical Oncology), Yale School of Medicine/Yale Cancer Center, New Haven, CT, USA

    Benjamin Newton MD & Anne C. Chiang MD, PhD

Authors
  1. Benjamin Newton MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne C. Chiang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin Newton MD .

Editor information

Editors and Affiliations

  1. Yale Comprehensive Cancer Center, Yale University, New Haevn, CT, USA

    Anne C. Chiang

  2. Yale Comprehensive Cancer Center, Yale University, New Haevn, CT, USA

    Roy S. Herbst

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Newton, B., Chiang, A.C. (2021). Therapeutic Advances in Small Cell Lung Cancer Management. In: Chiang, A.C., Herbst, R.S. (eds) Lung Cancer. Current Cancer Research. Humana, Cham. https://doi.org/10.1007/978-3-030-74028-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-74028-3_8

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-74027-6

  • Online ISBN: 978-3-030-74028-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation